ECSP055569A - Forma de dosificación de pramipexol en una dosis única diaria - Google Patents
Forma de dosificación de pramipexol en una dosis única diariaInfo
- Publication number
- ECSP055569A ECSP055569A EC2005005569A ECSP055569A ECSP055569A EC SP055569 A ECSP055569 A EC SP055569A EC 2005005569 A EC2005005569 A EC 2005005569A EC SP055569 A ECSP055569 A EC SP055569A EC SP055569 A ECSP055569 A EC SP055569A
- Authority
- EC
- Ecuador
- Prior art keywords
- daily dose
- single daily
- pramipexol
- dosage form
- pramipexole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a formulaciones farmacéuticas del agonista receptor de la dopamina pramipexol y más particularmente a formas de dosificación de liberación prolongada adecuadas para administración de pramipexol en una dosis única diaria.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39844702P | 2002-07-25 | 2002-07-25 | |
US39842702P | 2002-07-25 | 2002-07-25 | |
US47951403P | 2003-06-18 | 2003-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055569A true ECSP055569A (es) | 2005-04-18 |
Family
ID=31192088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005569A ECSP055569A (es) | 2002-07-25 | 2005-01-24 | Forma de dosificación de pramipexol en una dosis única diaria |
Country Status (40)
Country | Link |
---|---|
US (2) | US8679533B2 (es) |
EP (2) | EP1536792B1 (es) |
JP (1) | JP4607584B2 (es) |
KR (2) | KR20050025654A (es) |
CN (1) | CN1671381B (es) |
AP (1) | AP2223A (es) |
AR (1) | AR040682A1 (es) |
AU (1) | AU2003256921B2 (es) |
BR (1) | BR0312948A (es) |
CA (1) | CA2493629C (es) |
CU (1) | CU23468B7 (es) |
CY (2) | CY1114263T1 (es) |
DE (1) | DE20321906U1 (es) |
DK (2) | DK1536792T3 (es) |
EA (1) | EA017595B1 (es) |
EC (1) | ECSP055569A (es) |
ES (2) | ES2421787T3 (es) |
GE (1) | GEP20074047B (es) |
HK (1) | HK1078007A1 (es) |
HR (1) | HRP20041234B1 (es) |
IL (1) | IL166076A0 (es) |
IS (1) | IS7613A (es) |
MA (1) | MA27372A1 (es) |
ME (1) | ME00347B (es) |
MX (1) | MXPA05000980A (es) |
MY (1) | MY142204A (es) |
NO (1) | NO20050481L (es) |
NZ (1) | NZ562681A (es) |
OA (1) | OA12889A (es) |
PA (1) | PA8578501A1 (es) |
PE (1) | PE20040134A1 (es) |
PL (1) | PL375444A1 (es) |
PT (2) | PT2289514E (es) |
RS (1) | RS52764B (es) |
SG (1) | SG177011A1 (es) |
SI (2) | SI1536792T1 (es) |
TW (1) | TWI351955B (es) |
UY (1) | UY27913A1 (es) |
WO (1) | WO2004010999A1 (es) |
ZA (1) | ZA200500015B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
US7365086B2 (en) * | 2003-07-25 | 2008-04-29 | Synthon Ip Inc. | Pramipexole acid addition salts |
CN101843597A (zh) | 2004-08-13 | 2010-09-29 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途 |
SI1781260T2 (sl) * | 2004-08-13 | 2014-08-29 | Boehringer Ingelheim International Gmbh | Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol, postopek za izdelavo le-te in njena uporaba |
US20080038344A1 (en) * | 2004-10-01 | 2008-02-14 | Nippon Zoki Pharmaceutical Co., Ltd. | Solid Pharmaceutical Preparation |
WO2006046256A1 (en) * | 2004-10-27 | 2006-05-04 | Alembic Limited | Extended release formulation of pramipexole dihydrochloride |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
WO2007090882A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical extended release compositions comprising pramipexole |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
JP2009537565A (ja) | 2006-05-16 | 2009-10-29 | ノップ ニューロサイエンシーズ、インク. | R(+)およびs(−)プラミペキソール組成とそれを利用する方法 |
US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
US10716798B2 (en) | 2007-02-21 | 2020-07-21 | The Regents Of The University Of Michigan | Compositions and methods for tranquilizing heart muscle |
EP2137171A4 (en) | 2007-03-14 | 2010-05-19 | Knopp Neurosciences Inc | SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE |
WO2008145252A1 (en) * | 2007-05-25 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation comprising pramipexole |
WO2008150741A1 (en) * | 2007-06-04 | 2008-12-11 | Drugtech Corporation | Controlled release dopamine agonist compositions |
CA2725482A1 (en) * | 2008-06-09 | 2009-12-17 | Supernus Pharmaceuticals, Inc. | Controlled release formulations of pramipexole |
EP2334185A4 (en) | 2008-08-19 | 2011-09-21 | Knopp Neurosciences Inc | COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL |
WO2010115267A1 (en) * | 2009-04-09 | 2010-10-14 | Purdue Pharma | Once-daily oral ir/cr pramipexole formulation |
EP2448411A4 (en) * | 2009-07-02 | 2012-11-28 | Supernus Pharmaceuticals Inc | METHOD OF TREATING A NEUROLOGICAL DISORDER |
WO2011037976A2 (en) * | 2009-09-22 | 2011-03-31 | Dr. Reddy's Laboratories Limited | Pramipexole pharmaceutical formulations |
WO2011086182A2 (en) * | 2010-01-18 | 2011-07-21 | Synthon Bv | Pramipexole extended release tablets |
TR201001862A1 (tr) * | 2010-03-11 | 2011-10-21 | Sanovel �La� San.Ve T�C.A.�. | Kontrollü salım gerçekleştiren pramipeksol formülasyonları. |
WO2011128914A2 (en) | 2010-04-15 | 2011-10-20 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of pramipexole |
EP2575780A1 (en) | 2010-05-24 | 2013-04-10 | Lupin Limited | Extended release formulation of pramipexole |
CN102670550A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 盐酸普拉克索渗透泵型控释片 |
WO2013034173A1 (en) | 2011-09-06 | 2013-03-14 | Synthon Bv | Pramipexole extended release tablets |
CN102406626B (zh) * | 2011-12-02 | 2013-08-28 | 深圳海王药业有限公司 | 盐酸普拉克索缓释片剂及其制备方法 |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
EP2732812A1 (de) | 2012-11-15 | 2014-05-21 | Aristo Pharma GmbH | Pramipexol-Retardtablettenformulierung |
CN104744400B (zh) * | 2012-11-22 | 2017-08-11 | 北京三泉医药技术有限公司 | 用于治疗神经疾病的四氢苯并噻唑衍生物 |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
JP6329717B2 (ja) | 2013-07-12 | 2018-05-23 | ノップ バイオサイエンシーズ エルエルシー | 高好酸球値および/または高好塩基球値の治療 |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
EP3033081B1 (en) | 2013-08-13 | 2021-05-12 | Knopp Biosciences LLC | Compositions and methods for treating chronic urticaria |
WO2015023786A1 (en) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
CN104606162B (zh) * | 2015-01-07 | 2017-03-29 | 海南康虹医药科技开发有限公司 | 一种盐酸普拉克索缓释制剂及其制备方法 |
CN104784155B (zh) * | 2015-05-15 | 2018-02-23 | 中国药科大学 | 一种盐酸普拉克索组合微丸胶囊及其制备方法 |
CN105030721B (zh) * | 2015-08-30 | 2018-05-04 | 南京康川济医药科技有限公司 | 一种含有盐酸普拉克索的口服固体组合物 |
EP3522843B1 (en) * | 2016-10-07 | 2022-09-21 | Transwell Biotech Co., Ltd. | Pramipexole transdermal delivery system and uses thereof |
MX2019007128A (es) * | 2016-12-21 | 2019-09-19 | Hso Herbert Schmidt Gmbh & Co Kg | Solucion de decapado para decapar materiales sinteticos. |
EP3615024A4 (en) * | 2017-04-24 | 2021-01-20 | Chase Therapeutics Corporation | COMPOSITIONS AND METHODS OF TREATMENT FOR DEPRESSION |
CA3072994A1 (en) * | 2017-08-17 | 2019-02-21 | Zi-Qiang Gu | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887440A (en) * | 1957-08-12 | 1959-05-19 | Dow Chemical Co | Enteric coating |
US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
NL128902C (es) * | 1960-06-06 | |||
US3458622A (en) * | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
JPS58403B2 (ja) * | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
SE8003805L (sv) | 1980-05-21 | 1981-11-22 | Haessle Ab | En farmaceutisk beredning med forbettrade utlosningsegenskap |
SE8103843L (sv) * | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
ATE45735T1 (de) * | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US4666612A (en) * | 1986-03-17 | 1987-05-19 | Kerr-Mcgee Chemical Corporation | Method for recovering a wood preservative from waste sludges |
US4772473A (en) * | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
US4709712A (en) * | 1986-10-22 | 1987-12-01 | Dermatalogical Products Of Texas | Polycarboxylic acid polymer gels as protective agents |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4789549A (en) * | 1987-03-09 | 1988-12-06 | Warner-Lambert Company | Sustained release dosage forms |
US4859470A (en) * | 1988-06-02 | 1989-08-22 | Alza Corporation | Dosage form for delivering diltiazem |
GB8828020D0 (en) * | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5273975A (en) * | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
EP0447168A3 (en) | 1990-03-16 | 1993-01-07 | Yamanouchi Pharmaceutical Co. Ltd. | Long acting granular pharmaceutical composition |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5656296A (en) * | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
US5731338A (en) * | 1992-07-02 | 1998-03-24 | Oramed, Inc. | Controlled release pilocarpine delivery system |
SK281042B6 (sk) | 1992-09-18 | 2000-11-07 | Yamanouchi Pharmaceutical Co., Ltd | Prípravok hydrogélového typu s ustáleným uvoľňovaním |
DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5484608A (en) | 1994-03-28 | 1996-01-16 | Pharmavene, Inc. | Sustained-release drug delivery system |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
US5650420A (en) | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
SK283370B6 (sk) | 1995-12-27 | 2003-06-03 | Janssen Pharmaceutica N. V. | Bioadhezívna farmaceutická kompozícia a spôsob jej prípravy |
US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
JPH1017497A (ja) | 1996-07-02 | 1998-01-20 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
GB9619074D0 (en) | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
EP0998271B3 (en) * | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
EP1009387B1 (en) | 1997-07-02 | 2006-04-12 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
CA2211778A1 (en) | 1997-08-14 | 1999-02-14 | Francois Carriere | Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents |
US6624200B2 (en) * | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6248358B1 (en) * | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
DE69819748T2 (de) * | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
US7153845B2 (en) * | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
AU756693B2 (en) | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
US6197339B1 (en) * | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US20020054911A1 (en) * | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
GB9802201D0 (en) | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
CA2323177A1 (en) * | 1998-03-11 | 1999-09-16 | Susan Marie Milosovich | Composition |
JP2002515425A (ja) | 1998-05-15 | 2002-05-28 | ファルマシア・アンド・アップジョン・カンパニー | カバーゴリンおよびプラミペキソール:新たな使用および組合せ |
US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
TW407058B (en) * | 1998-07-17 | 2000-10-01 | Dev Center Biotechnology | Oral cisapride dosage forms with an extended duration |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
ATE313319T1 (de) * | 1999-03-31 | 2006-01-15 | Janssen Pharmaceutica Nv | Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe |
DE19927688A1 (de) * | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
ATE431141T1 (de) * | 1999-07-13 | 2009-05-15 | Alpha Res Group Llc | Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit |
GB9923045D0 (en) | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
WO2001022820A1 (en) | 1999-09-30 | 2001-04-05 | The General Hospital Corporation | Use of pramipexole as a treatment for cocaine craving |
CN1409630A (zh) | 1999-10-19 | 2003-04-09 | Nps药物有限公司 | 用于治疗cns-失调疾病之持续释放型制剂 |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
AU2731401A (en) * | 1999-12-22 | 2001-07-03 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
CA2332691C (en) * | 2000-01-27 | 2007-11-27 | The York Group, Inc. | Death care merchandising system |
DK2283842T3 (en) | 2000-02-08 | 2015-05-26 | Euro Celtique Sa | Oral opioid agonist formulations secured against forgery |
PE20011074A1 (es) * | 2000-02-23 | 2001-10-04 | Upjohn Co | Uso de pramipexol en el tratamiento de trastornos de adiccion |
CN1660435A (zh) * | 2000-02-24 | 2005-08-31 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US6277875B1 (en) | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
WO2002011727A1 (en) * | 2000-08-08 | 2002-02-14 | Teva Pharmaceutical Industries Ltd. | Stable pergolide mesylate and process for making same |
ES2187249B1 (es) * | 2000-09-18 | 2004-09-16 | Synthon Bv | Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles. |
SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
ES2398348T3 (es) | 2001-07-04 | 2013-03-15 | Sun Pharma Advanced Research Company Ltd | Sistema de administración de fármacos controlada por retención gástrica |
FR2827872A1 (fr) | 2001-07-30 | 2003-01-31 | Roussy Inst Gustave | Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire |
US20030032661A1 (en) * | 2001-08-02 | 2003-02-13 | Boehringer Ingelheim Pharma Kg | Pramipexole as an anticonvulsant |
GB0125088D0 (en) | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
AU2002358270A1 (en) * | 2001-12-20 | 2003-07-09 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
CN101410091A (zh) | 2002-01-04 | 2009-04-15 | Ivax研究公司 | 用于持续释放格列吡嗪的药物递送系统 |
ATE432689T1 (de) | 2002-03-04 | 2009-06-15 | Ipsen Pharma | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid |
ES2627298T3 (es) | 2002-04-05 | 2017-07-27 | Mundipharma Pharmaceuticals S.L. | Preparación farmacéutica que contiene oxicodona y naloxona |
IL164438A0 (en) | 2002-04-15 | 2005-12-18 | Adams Lab Inc | Sustaubed release of guaifenesin combination drugs |
US20030215498A1 (en) * | 2002-05-17 | 2003-11-20 | Harland Ronald S. | Rapidly disintegrating comressed tablets comprising biologically active compounds |
MXPA04012347A (es) | 2002-06-10 | 2005-02-25 | Wyeth Corp | Nueva sal formiato de o-desmetilvenlafaxina. |
AU2003257425A1 (en) | 2002-06-27 | 2004-01-19 | Cilag Ag | Spherical pellet containing a water-soluble active ingredient |
AU2003281181A1 (en) * | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
AR040680A1 (es) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Composicion de tabletas de liberacion sostenida |
CA2488860A1 (en) | 2002-07-25 | 2004-02-05 | Pharmacia Corporation | Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
WO2004058228A1 (en) | 2002-12-24 | 2004-07-15 | Lupin Limited | Enteric coated fluoxetine composition |
CA2415154C (en) | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
US20050020589A1 (en) * | 2003-06-18 | 2005-01-27 | Pfizer Inc. | Sustained-release tablet composition comprising a dopamine receptor agonist |
CN101843597A (zh) * | 2004-08-13 | 2010-09-29 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途 |
SI1781260T2 (sl) * | 2004-08-13 | 2014-08-29 | Boehringer Ingelheim International Gmbh | Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol, postopek za izdelavo le-te in njena uporaba |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
EP1886665A1 (en) * | 2006-08-01 | 2008-02-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Gastro retentive delivery system |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
EA200900270A1 (ru) * | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Системы регулируемого высвобождения и способ их приготовления |
-
2003
- 2003-07-24 MY MYPI20032783A patent/MY142204A/en unknown
- 2003-07-24 US US10/626,275 patent/US8679533B2/en active Active
- 2003-07-24 PA PA20038578501A patent/PA8578501A1/es unknown
- 2003-07-24 PE PE2003000736A patent/PE20040134A1/es not_active Application Discontinuation
- 2003-07-24 AR AR20030102667A patent/AR040682A1/es unknown
- 2003-07-25 PL PL03375444A patent/PL375444A1/xx unknown
- 2003-07-25 TW TW092120436A patent/TWI351955B/zh not_active IP Right Cessation
- 2003-07-25 AP AP2005003206A patent/AP2223A/xx active
- 2003-07-25 ME MEP-2008-522A patent/ME00347B/me unknown
- 2003-07-25 NZ NZ562681A patent/NZ562681A/en not_active IP Right Cessation
- 2003-07-25 DE DE20321906U patent/DE20321906U1/de not_active Expired - Lifetime
- 2003-07-25 AU AU2003256921A patent/AU2003256921B2/en not_active Expired
- 2003-07-25 MX MXPA05000980A patent/MXPA05000980A/es unknown
- 2003-07-25 SI SI200332311T patent/SI1536792T1/sl unknown
- 2003-07-25 RS RS115104A patent/RS52764B/en unknown
- 2003-07-25 PT PT101740892T patent/PT2289514E/pt unknown
- 2003-07-25 JP JP2004524936A patent/JP4607584B2/ja not_active Expired - Fee Related
- 2003-07-25 DK DK03771959.8T patent/DK1536792T3/da active
- 2003-07-25 ES ES10174089T patent/ES2421787T3/es not_active Expired - Lifetime
- 2003-07-25 SG SG2008086357A patent/SG177011A1/en unknown
- 2003-07-25 PT PT37719598T patent/PT1536792E/pt unknown
- 2003-07-25 SI SI200332276T patent/SI2289514T1/sl unknown
- 2003-07-25 KR KR1020057001294A patent/KR20050025654A/ko not_active Application Discontinuation
- 2003-07-25 BR BR0312948-9A patent/BR0312948A/pt not_active IP Right Cessation
- 2003-07-25 ES ES03771959.8T patent/ES2436745T3/es not_active Expired - Lifetime
- 2003-07-25 OA OA1200500017A patent/OA12889A/en unknown
- 2003-07-25 EP EP03771959.8A patent/EP1536792B1/en not_active Expired - Lifetime
- 2003-07-25 WO PCT/US2003/023522 patent/WO2004010999A1/en active Application Filing
- 2003-07-25 EA EA200500080A patent/EA017595B1/ru not_active IP Right Cessation
- 2003-07-25 GE GEAP8598A patent/GEP20074047B/en unknown
- 2003-07-25 DK DK10174089.2T patent/DK2289514T5/da active
- 2003-07-25 KR KR1020077012380A patent/KR101066374B1/ko not_active IP Right Cessation
- 2003-07-25 CN CN038178311A patent/CN1671381B/zh not_active Expired - Fee Related
- 2003-07-25 EP EP10174089.2A patent/EP2289514B9/en not_active Expired - Lifetime
- 2003-07-25 CA CA2493629A patent/CA2493629C/en not_active Expired - Fee Related
- 2003-07-31 UY UY27913A patent/UY27913A1/es not_active Application Discontinuation
-
2004
- 2004-12-23 IS IS7613A patent/IS7613A/is unknown
- 2004-12-30 IL IL16607604A patent/IL166076A0/xx unknown
- 2004-12-30 HR HRP20041234AA patent/HRP20041234B1/hr not_active IP Right Cessation
-
2005
- 2005-01-03 ZA ZA200500015A patent/ZA200500015B/en unknown
- 2005-01-24 EC EC2005005569A patent/ECSP055569A/es unknown
- 2005-01-25 MA MA28067A patent/MA27372A1/fr unknown
- 2005-01-25 CU CU20050019A patent/CU23468B7/es unknown
- 2005-01-27 NO NO20050481A patent/NO20050481L/no not_active Application Discontinuation
- 2005-11-09 HK HK05109990.6A patent/HK1078007A1/xx not_active IP Right Cessation
-
2013
- 2013-07-26 CY CY20131100643T patent/CY1114263T1/el unknown
- 2013-11-01 CY CY20131100969T patent/CY1114566T1/el unknown
-
2014
- 2014-01-28 US US14/165,743 patent/US20140141079A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055569A (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
ECSP055568A (es) | Composición de comprimido de liberación sostenida de pramipexol | |
UY30537A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
ECSP045238A (es) | Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente | |
ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
AR066420A1 (es) | Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso. | |
SV2009002857A (es) | Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo | |
GT200100175A (es) | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. | |
CL2008000823A1 (es) | Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras. | |
DK0954314T3 (da) | Doseringsformer til bedring af mandlig erektionsdefekt | |
TW200505498A (en) | Sugar-free oral transmucosal solid dosage forms and uses thereof | |
CR9262A (es) | Formulaciones en tableta de cci-1179 oralmente biodisponibles | |
UY27908A1 (es) | Formulaciones y formas de dosificación para la administración controlada de topiramato | |
AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
AR054595A1 (es) | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis | |
CL2008000750A1 (es) | Metodo para la administracion de una dosis semanal de 2-[6-(3-amino-piperidin-1-il)3-metil-2,4 dioxo-3,4 dihidro-2h-pirimidin-1-il metil]-4 fluoro-benzonitrilo; composicion farmaceutica de una forma de dosificacion individual de dicho compuesto; y su | |
ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
MY169068A (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
CL2007002574A1 (es) | Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson. | |
AR066924A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
CO5200840A1 (es) | Combinacion de sustancias activas con clonidina | |
BR0112847A (pt) | Uso de uma forma de dosagem sólida | |
AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
TR200200978T2 (tr) | Yeni mirtazapin formülasyonu |